PDF(Pubmed)
Abstract：
UNASSIGNED: We aimed to evaluate the effects of sintilimab plus radiotherapy on levels of Spondin-2 and glucose transporter-1 (Glut-1) in patients with cervical cancer.
UNASSIGNED: A total of 112 patients with cervical cancer treated from January 2019 to January 2021 were selected in this randomized control trial and divided into a control group (n = 56) and a study group (n = 56) using the random number table method. Chemotherapy using docetaxel + cisplatin was performed for both groups, based on which the control group was given radiotherapy (external conformal radiotherapy + intracavitary irradiation), and the study group received sintilimab plus radiotherapy. The treatment lasted for six cycles, with 21 days as one cycle.
UNASSIGNED: The total response rate of the study group was higher than that of the control group (55.36% vs 33.93%) (P < 0.05). There were no significant differences in adverse effects between the two groups (P > 0.05). After six cycles of treatment, the levels of carcinoembryonic antigen, squamous cell carcinoma antigen, vascular endothelial growth factor-A, vascular endothelial growth factor receptor 2, Spondin-2 and Glut-1 decreased in both groups compared with those before treatment, and they were lower in the study group (P < 0.05). The survival rate of the study group was higher than that of the control group (87.50% vs 71.43%) (P < 0.05).
UNASSIGNED: Sintilimab plus radiotherapy can effectively reduce the levels of serum tumor markers, such as Spondin-2 and Glut-1, and enhance the clinical efficacy on patients with cervical cancer, without increasing adverse effects.
UNASSIGNED: A total of 112 patients with cervical cancer treated from January 2019 to January 2021 were selected in this randomized control trial and divided into a control group (n = 56) and a study group (n = 56) using the random number table method. Chemotherapy using docetaxel + cisplatin was performed for both groups, based on which the control group was given radiotherapy (external conformal radiotherapy + intracavitary irradiation), and the study group received sintilimab plus radiotherapy. The treatment lasted for six cycles, with 21 days as one cycle.
UNASSIGNED: The total response rate of the study group was higher than that of the control group (55.36% vs 33.93%) (P < 0.05). There were no significant differences in adverse effects between the two groups (P > 0.05). After six cycles of treatment, the levels of carcinoembryonic antigen, squamous cell carcinoma antigen, vascular endothelial growth factor-A, vascular endothelial growth factor receptor 2, Spondin-2 and Glut-1 decreased in both groups compared with those before treatment, and they were lower in the study group (P < 0.05). The survival rate of the study group was higher than that of the control group (87.50% vs 71.43%) (P < 0.05).
UNASSIGNED: Sintilimab plus radiotherapy can effectively reduce the levels of serum tumor markers, such as Spondin-2 and Glut-1, and enhance the clinical efficacy on patients with cervical cancer, without increasing adverse effects.
摘要：
■我们旨在评估sintilimab联合放疗对宫颈癌患者Sondin-2和葡萄糖转运蛋白-1（Glut-1）水平的影响。
■选择2019年1月至2021年1月收治的宫颈癌患者112例，采用随机数字表法分为对照组(n=56)和研究组(n=56)。两组均使用多西他赛+顺铂进行化疗，对照组给予放疗(外适形放疗+腔内照射),研究组接受辛替利玛联合放疗。治疗持续了六个周期，21天为一个周期。
■研究组总有效率高于对照组(55.36%vs33.93%)(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。经过六个周期的治疗，癌胚抗原的水平，鳞状细胞癌抗原，血管内皮生长因子A,与治疗前相比，两组血管内皮生长因子受体2，Sondin-2和Glut-1均降低，研究组低于对照组(P<0.05)。研究组生存率为87.50%,对照组为71.43%,差异有统计学意义(P<0.05)。
■Sintilimab加放疗可有效降低血清肿瘤标志物水平，如Spondin-2和Glut-1，提高宫颈癌患者的临床疗效，不会增加不良影响。
■选择2019年1月至2021年1月收治的宫颈癌患者112例，采用随机数字表法分为对照组(n=56)和研究组(n=56)。两组均使用多西他赛+顺铂进行化疗，对照组给予放疗(外适形放疗+腔内照射),研究组接受辛替利玛联合放疗。治疗持续了六个周期，21天为一个周期。
■研究组总有效率高于对照组(55.36%vs33.93%)(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。经过六个周期的治疗，癌胚抗原的水平，鳞状细胞癌抗原，血管内皮生长因子A,与治疗前相比，两组血管内皮生长因子受体2，Sondin-2和Glut-1均降低，研究组低于对照组(P<0.05)。研究组生存率为87.50%,对照组为71.43%,差异有统计学意义(P<0.05)。
■Sintilimab加放疗可有效降低血清肿瘤标志物水平，如Spondin-2和Glut-1，提高宫颈癌患者的临床疗效，不会增加不良影响。
